Dragana Novina
Psychiatric/Mental Health · Valparaiso, INNPI 1851964894
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.4%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by AbbVie at 46.0% of the total. 2025 is the largest year on record at $8,594, 9.9 times the $869 reported in 2023. Among psychiatric/mental health clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 361 payments — averaging $32.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$606
- Tris Pharma Inc$518
- Otsuka America Pharmaceutical, Inc.$506
- Supernus Pharmaceuticals, Inc.$414
- Lundbeck LLC$403
- plus $4K from 22 others
What the payments were for
- Consulting fees$1151%
- Speaking & faculty fees$5,00043%
- Food & beverage$6,60956%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 21 | $5,397 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 28 | $606 |
| Tris Pharma Inc | 29 | $518 |
| Otsuka America Pharmaceutical, Inc. | 29 | $506 |
| Supernus Pharmaceuticals, Inc. | 37 | $414 |
| Lundbeck LLC | 26 | $403 |
| Neurocrine Biosciences, Inc. | 18 | $402 |
| Vanda Pharmaceuticals Inc. | 11 | $384 |
| Corium, LLC | 22 | $338 |
| Axsome Therapeutics, Inc. | 18 | $337 |
| Teva Pharmaceuticals USA, Inc. | 19 | $325 |
| Johnson & Johnson | 14 | $312 |
| E.r. Squibb & Sons, L.L.C. | 17 | $288 |
| Alkermes, Inc. | 16 | $226 |
| Almatica Pharma LLC | 11 | $187 |
| Noven Therapeutics, LLC | 8 | $151 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $150 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $125 |
| Janssen Scientific Affairs, LLC | 1 | $115 |
| OWP Pharmaceuticals, Inc. | 5 | $99 |
| Ironshore Pharmaceuticals Inc. | 5 | $98 |
| Idorsia Pharmaceuticals US Inc | 6 | $95 |
| Pfizer | 3 | $73 |
| Harmony Biosciences LLC | 3 | $64 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $39 |
| Acadia Pharmaceuticals Inc | 1 | $32 |
| Collegium Pharmaceutical, Inc. | 1 | $24 |
| Bausch Health US, LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,724 in reported general payments places this provider in the 95th percentile of 729 psychiatric/mental health providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LybalviOlanzapine/Samidorphan Malate | 12 | $18,350 |
| Duloxetine Hcl | 32 | $1,507 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 28 | $590 |
| Quetiapine Fumarate | 16 | $568 |
| Sertraline Hcl | 19 | $525 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 12 | $476 |
| Bupropion XlBupropion Hcl | 15 | $474 |
| Olanzapine | 16 | $162 |
| Alprazolam | 34 | $116 |
| Escitalopram Oxalate | 13 | $106 |
| Clonazepam | 22 | $56 |
| Trazodone Hcl | 13 | $54 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alkermes, Inc.Lybalvi | $226 | $18,35012 claims |
| Almatica Pharma LLCSertraline Hcl | $187 | $52519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 729 psychiatric/mental health providers in Indiana.
Other psychiatric/mental health in Valparaiso
- Brooke KempfTerre Haute$1.1M
- Gerald LewisMerrillville$336K
- Lauren LutzColumbus$320K
- Sonya RuedlingerIndianapolis$134K
- Trina GreenwaldMarion$107K
- Paul DuncanJeffersonville$46K
- Morgan StamperConnersville$42K
- Jennifer JimenezUnion Mills$37K
- Savannah MullinsClarksville$31K
- Sharon ClevengerFort Wayne$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.